X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Univercells will test in vitro and in vivo a proprietary mRNA vaccine delivered with Altamira’s SemaPhore nanoparticle platform to prevent, treat, and cure diseases in a range of fields from oncology to infectious diseases.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Univercells
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 25, 2024
Details:
Bentrio (AM-301) is an OTC drug-free gel nasal spray for personal protection against airborne allergens and, where approved, against airborne viruses. Upon application into the nose, bentrio forms a protective gel layer on the nasal mucosa.
Lead Product(s): AM-301
Therapeutic Area: Immunology Product Name: Bentrio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
Under the agreement, Pharma Nordic will market and commercialize Bentrio (bentonite), a nasal spray for protection against airborne allergens, in Norway and potentially further Scandinavian countries.
Lead Product(s): Bentonite
Therapeutic Area: Immunology Product Name: Bentrio
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Pharma Nordic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 20, 2023
Details:
The Company intends to use the net proceeds for research and development of AM-401, an intravenously administered nanoparticle based on the OligoPhore™ platform targeting KRAS.
Lead Product(s): AM-401
Therapeutic Area: Oncology Product Name: AM-401
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 06, 2023
Details:
Under the terms of the agreement, Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform and comprising certain non-coding RNAs (ncRNAs) for the development of genetic medicines to reverse the damage of ischemic heart disease.
Lead Product(s): Genetic Medicine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Heqet Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 05, 2023
Details:
AM-125 is a patented intranasal formulation of betahistine dihydrochloride. It has been shown to have 5 to 29 times higher bioavailability than orally administeration. It is being developed for the treatment of acute vestibular syndrome.
Lead Product(s): Betahistine Dihydrochloride
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: AM-125
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
AM-301 (bentrio) is an OTC drug-free gel nasal spray for personal protection against airborne allergens and, where approved, against airborne viruses. Upon application into the nose, bentrio forms a protective gel layer on the nasal mucosa.
Lead Product(s): AM-301
Therapeutic Area: Immunology Product Name: Bentrio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
AM-125 is a patented intranasal formulation of betahistine. It has been shown to have 5-to-29 times higher bioavailability than orally administeration. It is being developed for the treatment of acute vestibular syndrome.
Lead Product(s): Betahistine Dihydrochloride
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: AM-125
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
SemaPhore is a versatile platform for safe and effective delivery of mRNA into target cells. It is based on a patented 21-amino acid peptide that can engage any type of RNA in rapid self-assembly into a polyplex. It has demonstrated efficacy in various murine disease models.
Lead Product(s): mRNA-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
Details:
AM-125 is a patented intranasal formulation of betahistine dihydrochloride. It has been shown to have 5-to-29 times higher bioavailability than orally administeration. It is being developed for the treatment of acute vestibular syndrome.
Lead Product(s): Betahistine Dihydrochloride
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: AM-125
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
